PHARMING GRP SP. ADRS Market Cap ($762.66 Million)
Market Cap & Net Worth: PHARMING GRP SP. ADRS (PHG)
PHARMING GRP SP. ADRS market cap. PHARMING GRP SP. ADRS (F:PHG) has a market capitalization of $762.66 Million (€652.34 Million) as of November 1, 2026. Listed on the F stock exchange, this Germany-based company holds position #9748 globally and #1207 in its home market, demonstrating a -4.79% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PHARMING GRP SP. ADRS's stock price €13.90 by its total outstanding shares 68514762 (68.51 Million). Also see cash efficiency ratio of PHARMING GRP SP. ADRS for how efficiently the company converts equity into cash flow.
PHARMING GRP SP. ADRS Market Cap History (2021–2026)
PHARMING GRP SP. ADRS market cap history from 2021 to 2026. Data shows growth from $580.73 Million to $857.08 Million (3.89% CAGR). Check current stock price of PHARMING GRP SP. ADRS for real-time trading data and today's change.
PHARMING GRP SP. ADRS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PHARMING GRP SP. ADRS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore PHG year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.92x
PHARMING GRP SP. ADRS's market cap is 2.92 times its annual revenue
Latest Price to Earnings (P/E) Ratio
384.91x
PHARMING GRP SP. ADRS's market cap is 384.91 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $580.73 Million | $198.87 Million | $16.00 Million | 2.92x | 36.30x |
| 2022 | $817.03 Million | $205.62 Million | $13.67 Million | 3.97x | 59.75x |
| 2023 | $809.02 Million | $245.32 Million | -$10.55 Million | 3.30x | N/A |
| 2024 | $728.92 Million | $297.20 Million | -$11.84 Million | 2.45x | N/A |
| 2025 | $1.10 Billion | $376.13 Million | $2.85 Million | 2.92x | 384.91x |
Competitor Companies of PHG by Market Capitalization
Companies near PHARMING GRP SP. ADRS in the global market cap rankings as of November 1, 2026. Also see how large is PHARMING GRP SP. ADRS's balance sheet for a full breakdown of the balance sheet.
Key companies related to PHARMING GRP SP. ADRS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of PHARMING GRP SP. ADRS (2021–2026)
Market capitalization of PHARMING GRP SP. ADRS from 2021 to today. Between 2021 and today, PHARMING GRP SP. ADRS's market cap moved from $580.73 Million to $ 857.08 Million, with a yearly change of 3.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €857.08 Million | -21.90% |
| 2025 | €1.10 Billion | +50.55% |
| 2024 | €728.92 Million | -9.90% |
| 2023 | €809.02 Million | -0.98% |
| 2022 | €817.03 Million | +40.69% |
| 2021 | €580.73 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of PHARMING GRP SP. ADRS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $762.66 Million USD |
| MoneyControl | $762.66 Million USD |
| MarketWatch | $762.66 Million USD |
| marketcap.company | $762.66 Million USD |
| Reuters | $762.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PHARMING GRP SP. ADRS
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more